Skip to main content

Infectious Disease

4
Pipeline Programs
7
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Vaccine
150%
+ 7 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Relief Therapeutics
Relief TherapeuticsSwitzerland - Geneva
1 program
1
7-valent pneumococcal conjugated vaccinePhase 4Vaccine1 trial
Active Trials
NCT02040402Completed100Est. Dec 2010
Gangagen
GangagenIndia - Bangalore
1 program
1
P128-0.1 mgPhase 1/21 trial
Active Trials
NCT01746654Completed74Est. Dec 2015
MSD
MSDIreland - Ballydine
2 programs
1
MK-7655Phase 11 trial
Pharmacist-led InterventionN/A1 trial
Active Trials
NCT03239665Completed335Est. Aug 2019
NCT01275170Completed49Est. Mar 2012
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
MK-7655Phase 1
Pharmacist-led InterventionN/A
Labcorp
LabcorpBURLINGTON, NC
1 program
District health information packageN/A1 trial
Active Trials
NCT01003587Unknown594Est. Jul 2016
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
MK-7655PHASE_1
FUJIFILM Pharma
FUJIFILM PharmaMA - Cambridge
1 program
favipiravirPHASE_1Small Molecule1 trial
Active Trials
NCT06024421Recruiting39Est. Nov 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Relief Therapeutics7-valent pneumococcal conjugated vaccine
GangagenP128-0.1 mg
FUJIFILM Pharmafavipiravir
MSDMK-7655
MSDPharmacist-led Intervention
LabcorpDistrict health information package

Clinical Trials (6)

Total enrollment: 1,191 patients across 6 trials

NCT02040402Relief Therapeutics7-valent pneumococcal conjugated vaccine

Immunogenicity of 3+1 Versus 2+1 Schedule for PCV7

Start: Feb 2009Est. completion: Dec 2010100 patients
Phase 4Completed
NCT01746654GangagenP128-0.1 mg

Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients

Start: Dec 2012Est. completion: Dec 201574 patients
Phase 1/2Completed
NCT06024421FUJIFILM Pharmafavipiravir

Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers

Start: May 2024Est. completion: Nov 202739 patients
Phase 1Recruiting
NCT01275170MSDMK-7655

A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

Start: Jan 2011Est. completion: Mar 201249 patients
Phase 1Completed
NCT03239665MSDPharmacist-led Intervention

Vaccination Education Through Pharmacists and Senior Centers (VEPSC)

Start: Oct 2017Est. completion: Aug 2019335 patients
N/ACompleted
NCT01003587LabcorpDistrict health information package

Promoting Evidence-Based Decision-Making in India: District Evaluation Study on Health

Start: Jul 2009Est. completion: Jul 2016594 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,191 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.